2017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn H, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D, Huang C, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne K, Pagani O, Partridge A, Pritchard K, Ro J, Rutgers E, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan T, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals Of Oncology 2017, 28: 1700-1712. PMID: 28838210, PMCID: PMC6246241, DOI: 10.1093/annonc/mdx308.Peer-Reviewed Original ResearchConceptsLow-risk patientsBreast cancerNeoadjuvant therapyPostmenopausal womenEarly-stage breast cancerER-positive breast cancerAvoidance of chemotherapyDe-escalate therapyAdjuvant endocrine treatmentRegional nodal irradiationHigh-risk patientsEarly breast cancerSentinel node biopsyHigh-risk tumorsPositive breast cancerBreast cancer recurrenceExpert consensus conferenceSubstantial new evidenceNodal irradiationBisphosphonate useEndocrine treatmentNeoadjuvant treatmentOvarian suppressionPremenopausal womenPrimary therapy
2015
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. New England Journal Of Medicine 2015, 372: 134-141. PMID: 25564897, PMCID: PMC4313867, DOI: 10.1056/nejmoa1406281.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleFollow-Up StudiesHumansInfusions, IntravenousMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalPaclitaxelRadiotherapyReceptor, ErbB-2Survival RateTrastuzumabConceptsHER2-positive breast cancerBreast cancerAdjuvant paclitaxelEjection fractionInvasive diseaseStage I HER2-positive breast cancerHuman epidermal growth factor receptor type 2Epidermal growth factor receptor type 2Symptomatic congestive heart failureHER2-negative breast cancerLeft ventricular ejection fractionDistant metastatic breast cancerFactor receptor type 2Discontinuation of trastuzumabGrade 3 neuropathySingle standard treatmentPrimary end pointCongestive heart failureMetastatic breast cancerVentricular ejection fractionPositive breast cancerInvestigator-initiated studyReceptor type 2Disease-specific eventsMedian follow
2010
Outcomes following local therapy for early-stage breast cancer in non-trial populations
Keating NL, Landrum MB, Brooks JM, Chrischilles EA, Winer EP, Wright K, Volya R. Outcomes following local therapy for early-stage breast cancer in non-trial populations. Breast Cancer Research And Treatment 2010, 125: 803-813. PMID: 20376555, PMCID: PMC2924956, DOI: 10.1007/s10549-010-0865-4.Peer-Reviewed Original ResearchConceptsBreast-conserving surgeryEarly-stage breast cancerClinical trialsBreast cancerEarly-stage breast cancer patientsPrimary breast cancer therapyPrimary breast cancer treatmentEnd Results cancer registryNon-trial populationBreast cancer patientsPopulation-based dataBreast cancer treatmentBreast cancer therapyNon-selected populationPropensity score analysisMedicare administrative dataMore mastectomiesPrimary therapyLocal therapySurveillance EpidemiologyAdjusted survivalCancer RegistryCancer patientsHospital characteristicsMastectomy
2007
Brain Metastases: The HER2 Paradigm
Lin NU, Winer EP. Brain Metastases: The HER2 Paradigm. Clinical Cancer Research 2007, 13: 1648-1655. PMID: 17363517, DOI: 10.1158/1078-0432.ccr-06-2478.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerCNS diseaseBreast cancerCentral nervous system metastasesExtra-CNS diseaseImportant sanctuary siteNervous system metastasesProportion of patientsTerms of prognosisCNS metastasesCNS progressionBrain metastasesCytotoxic chemotherapySystemic therapyAdvanced cancerTherapeutic challengePrimary diagnosisHistorical controlsTargeted therapyPreventive strategiesSanctuary siteTumor subtypesParticular tumor subtypesPatientsNatural historyInvasive breast cancer.
Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Invasive breast cancer. Journal Of The National Comprehensive Cancer Network 2007, 5: 246-312. PMID: 17439758, DOI: 10.6004/jnccn.2007.0025.Peer-Reviewed Original ResearchConceptsInvasive breast cancerBreast cancerBreast cancer mortalityAmerican Cancer SocietyMore effective treatmentsCommon malignancyCancer mortalityCancer deathLung cancerCancer SocietyEffective treatmentNew casesCancerEarly detectionUnited StatesTreatmentGuidelinesMalignancyMortalityIncidenceDiseaseDiagnosisWomen
2004
Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer
Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. New England Journal Of Medicine 2004, 351: 971-977. PMID: 15342805, DOI: 10.1056/nejmoa040587.Peer-Reviewed Original ResearchConceptsWomen 70 yearsEarly breast cancerBreast cancerOverall survivalRegional recurrenceDistant metastasisRadiation therapyEstrogen receptor-positive breast carcinomasFrequency of mastectomyClinical stage IPrimary end pointFive-year ratesRate of mastectomyPositive breast cancerYears of ageSignificant differencesAdjuvant therapyAdverse eventsSpecific survivalLocal recurrenceCosmetic resultsOnly significant differenceBreast carcinomaLumpectomyStage I
2003
Amifostine and chemoradiation therapy: ASCO responds
Schuchter L, Meropol NJ, Winer EP, Hensley ML, Somerfield MR. Amifostine and chemoradiation therapy: ASCO responds. The Lancet Oncology 2003, 4: 593. PMID: 14554234, DOI: 10.1016/s1470-2045(03)01216-6.Peer-Reviewed Original Research
2002
2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology*
Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology*. Journal Of Clinical Oncology 2002, 20: 2895-2903. PMID: 12065567, DOI: 10.1200/jco.2002.04.178.Peer-Reviewed Original Research
2000
Primary Care for Survivors of Breast Cancer
Burstein HJ, Winer EP. Primary Care for Survivors of Breast Cancer. New England Journal Of Medicine 2000, 343: 1086-1094. PMID: 11027744, DOI: 10.1056/nejm200010123431506.Peer-Reviewed Original ResearchDexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique.
Hellmann K, Hensley M, Schuchter L, Winer E, Meropol N, Pfister D. Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique. Journal Of Clinical Oncology 2000, 18: 2004-6. PMID: 10784645, DOI: 10.1200/jco.2000.18.9.2004.Peer-Reviewed Original Research
1999
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley M, Schuchter L, Lindley C, Meropol N, Cohen G, Broder G, Gradishar W, Green D, Langdon R, Mitchell R, Negrin R, Szatrowski T, Thigpen J, VonHoff D, Wasserman T, Winer E, Pfister D. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. Journal Of Clinical Oncology 1999, 17: 3333-55. PMID: 10506637, DOI: 10.1200/jco.1999.17.10.3333.Peer-Reviewed Original ResearchConceptsUse of dexrazoxaneMetastatic breast cancerClinical practice guidelinesUrothelial toxicityTumor protectionBreast cancerInsufficient evidencePractice guidelinesClinical Oncology Clinical Practice GuidelineLong-term patient qualityOncology Clinical Practice GuidelineStem cell transplantation settingUse of mesnaAnthracycline-containing regimensCardiac risk factorsUse of chemotherapyGrades of RecommendationRadiotherapy-related toxicityMultidisciplinary expert panelLong-term chemotherapyClinical treatment trialsDuration of treatmentLevel of evidenceReduction of nephrotoxicityAmerican Society
1998
Complications of axillary lymph node dissection for carcinoma of the breast
Warmuth M, Bowen G, Prosnitz L, Chu L, Broadwater G, Peterson B, Leight G, Winer E. Complications of axillary lymph node dissection for carcinoma of the breast. Cancer 1998, 83: 1362-1368. PMID: 9762937, DOI: 10.1002/(sici)1097-0142(19981001)83:7<1362::aid-cncr13>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsAxillary lymph node dissectionLymph node dissectionNode dissectionBreast carcinomaYounger ageGreater body surface areaTreatment factorsAdjuvant tamoxifen therapyEpisodes of infectionHistory of smokingLong-term complicationsMajority of symptomsFrequency of inflammationLong-term symptomsBody surface areaDaily activitiesCross-sectional surveySelf-administered questionnaireArm swellingTamoxifen therapySevere complicationsTerm complicationsYounger patientsPrimary managementRecurrence 2